Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04682548 · ClinicalTrials.gov registry record
Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 920
- Enrollment target
NCT04682548: Completed study, sponsored by NYU Langone Health.
NCT04682548 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 920 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04682548 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 920 participants
- Enrollment target
Study Summary
This non-interventional, biospecimen collection study is designed to help us better understand whether MS patients have impaired immune defenses to COVID-19 infection. The potential influence of immune modulating medications for MS will be considered through these exploratory studies. This study is also designed to provide context for interpretation of anti-SARS CoV2 serologies in MS patients during convalescence from COVID-19 infection.
Primary Outcome
Seropositivity rate against SARS-CoV-2 (nucleocapsid and/or spike proteins, as available) as measured by the Roche DIA antibody assay in MS patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 920 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2022-09-15 |
What the finished NCT04682548 record still lists
NCT04682548 is an observational study that tracks outcomes without assigning an intervention. The registered 920 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04682548 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04682548 about?
NCT04682548 is a clinical study titled "Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients". This non-interventional, biospecimen collection study is designed to help us better understand whether MS patients have impaired immune defenses to COVID-19 infection. The potential influence of immune modulating medications for MS will be considered through these exploratory studies. This study is ...
What is the current status of trial NCT04682548?
This trial is currently completed. The enrollment target is 920 participants. The study started on 2021-01-05. Estimated completion is 2022-09-15.
Who is sponsoring clinical trial NCT04682548?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04589845 · 920 participants · Phase 2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- NCT06109870 · 920 participants · NA
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
- NCT06957366 · 920 participants · NA
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
- NCT07174336 · 920 participants · Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI